# Performance and Acceptance of Optive Versus Hylocomod Eyedrops in Patients With Dry Eye Symptoms

> **NCT00761202** · PHASE4 · COMPLETED · sponsor: **Allergan** · enrollment: 50 (actual)

## Conditions studied

- Dry Eye Syndromes

## Interventions

- **DRUG:** A sterile solution containing sodium carboxymethylcellulose and glycerin, preserved with PURITE®
- **DRUG:** Sodium hyaluronate

## Key facts

- **NCT ID:** NCT00761202
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2008-06
- **Final completion:** 2008-06
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2013-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00761202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00761202, "Performance and Acceptance of Optive Versus Hylocomod Eyedrops in Patients With Dry Eye Symptoms". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00761202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*